993 related articles for article (PubMed ID: 12888902)
21. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
Totzke G; Schulze-Osthoff K; Jänicke RU
Oncogene; 2003 Sep; 22(39):8021-30. PubMed ID: 12970750
[TBL] [Abstract][Full Text] [Related]
22. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
Shin YK; Park JS; Kim HS; Jun HJ; Kim GE; Suh CO; Yun YS; Pyo H
Cancer Res; 2005 Oct; 65(20):9501-9. PubMed ID: 16230415
[TBL] [Abstract][Full Text] [Related]
23. The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function.
Yan YX; Li WZ; Huang YQ; Liao WX
Prostaglandins Other Lipid Mediat; 2012 Jan; 97(1-2):29-35. PubMed ID: 21835258
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
[TBL] [Abstract][Full Text] [Related]
25. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
26. Nimesulide and indomethacin induce apoptosis in head and neck cancer cells.
Pelzmann M; Thurnher D; Gedlicka C; Martinek H; Knerer B
J Oral Pathol Med; 2004 Nov; 33(10):607-13. PubMed ID: 15482327
[TBL] [Abstract][Full Text] [Related]
27. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Liu B; Shi ZL; Feng J; Tao HM
Cell Biol Int; 2008 May; 32(5):494-501. PubMed ID: 18078766
[TBL] [Abstract][Full Text] [Related]
28. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Bae SH; Jung ES; Park YM; Kim BS; Kim BK; Kim DG; Ryu WS
Clin Cancer Res; 2001 May; 7(5):1410-8. PubMed ID: 11350912
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53.
Swamy MV; Herzog CR; Rao CV
Cancer Res; 2003 Sep; 63(17):5239-42. PubMed ID: 14500353
[TBL] [Abstract][Full Text] [Related]
30. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
Souza RF; Shewmake K; Beer DG; Cryer B; Spechler SJ
Cancer Res; 2000 Oct; 60(20):5767-72. PubMed ID: 11059772
[TBL] [Abstract][Full Text] [Related]
31. Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells.
Chen PY; Long QC
Acta Pharmacol Sin; 2004 Jul; 25(7):943-9. PubMed ID: 15210070
[TBL] [Abstract][Full Text] [Related]
32. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
Ding XZ; Tong WG; Adrian TE
Anticancer Res; 2000; 20(4):2625-31. PubMed ID: 10953335
[TBL] [Abstract][Full Text] [Related]
33. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Piazza GA; Rahm AK; Finn TS; Fryer BH; Li H; Stoumen AL; Pamukcu R; Ahnen DJ
Cancer Res; 1997 Jun; 57(12):2452-9. PubMed ID: 9192825
[TBL] [Abstract][Full Text] [Related]
34. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
[TBL] [Abstract][Full Text] [Related]
35. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
36. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
Leahy KM; Ornberg RL; Wang Y; Zweifel BS; Koki AT; Masferrer JL
Cancer Res; 2002 Feb; 62(3):625-31. PubMed ID: 11830509
[TBL] [Abstract][Full Text] [Related]
37. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
Elder DJ; Halton DE; Hague A; Paraskeva C
Clin Cancer Res; 1997 Oct; 3(10):1679-83. PubMed ID: 9815550
[TBL] [Abstract][Full Text] [Related]
38. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.
Williams CS; Watson AJ; Sheng H; Helou R; Shao J; DuBois RN
Cancer Res; 2000 Nov; 60(21):6045-51. PubMed ID: 11085526
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
Levitt RJ; Pollak M
Cancer Res; 2002 Dec; 62(24):7372-6. PubMed ID: 12499282
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
Wu R; Abramson AL; Shikowitz MJ; Dannenberg AJ; Steinberg BM
Clin Cancer Res; 2005 Sep; 11(17):6155-61. PubMed ID: 16144915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
